|
|
Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future? |
Sophie Knipper(),Gunhild von Amsberg,Franziska Stolzenbach,Thomas Steuber,Matthias Heck,Matthias Eiber,Christoph Berliner,Tobias Maurer
|
Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany |
|
|
|
Available online: 20 April 2021
|
Corresponding Authors:
Sophie Knipper
E-mail: a.knipper@uke.de
|
|
|
|
PSMA PET and SPECT imaging. (A) Initial 68Ga-PSMA-11 PET (maximum-intensity-projection) showing bilateral pelvic, as well as retroperitoneal lymphatic dissemination (arrows); (B) Example of initial retroperitoneal lymph node metastasis (circles; axial 68Ga-PSMA-11 PET/CT fusion image); (C) Complete remission of lymph node metastasis after chemo-hormonal therapy (axial 18F-rhPSMA-7 PET/CT fusion image); (D and E) Solitary recurrent retroperitoneal lymph node metastasis after radical prostatectomy (D. Axial 18F-rhPSMA-7 PET/CT fusion image; E. Axial 99mTc-PSMA-I&S SPECT/CT fusion image obtained prior to PSMA-radioguided salvage surgery). PSMA, prostatespecific membrane antigen; PET, positron emission tomography; SPECT, single photon emission computed tomography; CT, computed tomography; 99mTc‐PSMA‐I&S, 99mTc‐PSMA investigation and surgery.
|
[1] |
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancerdUpdated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2019; 77:403e17.
|
[2] |
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016; 13:226e35.
|
[3] |
Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018; 74:179e90.
|
[4] |
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm,multistage, platform randomised controlled trial. Lancet Lond Engl 2016 19;387:1163e77.
|
[5] |
Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99mTechnetium-based Prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol 2019; 75:659e66.
|
[6] |
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic,castration-sensitive prostate cancer. N Engl J Med 2017; 377:352e60.
|
[7] |
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378:1408e18.
|
[8] |
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana GomesAJ, Given R, et al. Apalutamide formetastatic, castrationsensitive prostate cancer. N Engl J Med 2019; 381:13e24.
|
[9] |
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed,metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet Lond Engl 2018; 392:2353e66.
|
[10] |
Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and casecontrol study. J Urol 2015; 193:832e8.
|
[11] |
Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016; 69:788e94.
|
[12] |
Horn T, Kr?nke M, Rauscher I, Haller B, Robu S, Wester HJ, et al. Single lesion on prostate-specific membrane antigenligand positron emission tomography and low prostatespecific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigentargeted radioguided surgery in recurrent prostate cancer. Eur Urol 2019; 76:517e23.
|
[13] |
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective,randomized, multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol 2018; 36:446e53.
|
[14] |
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 2018; 74:455e62.
|
[15] |
Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, et al. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Int J Canc 2020; 146:161e8.
|
No related articles found! |
|
|
|
|